title: Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.
abstract: On the basis of our clinical findings that the ability of cancer patients to generate lymphokine-activated killer cells became markedly augmented after mitomycin C administration, we designed a treatment regimen comprising mitomycin C 12 mg/m2, i.v. on day 1 and recombinant interleukin-2 700 U/m2 (8000 IU/kg), i.v. every 12 h from day 4 through day 8. The treatment course was repeated at almost 7-day intervals. Altogether 33 patients with advanced carcinoma, including mainly gastrointestinal carcinoma, were treated with this regimen. Of these, 10 had a partial response (PR) and 4 had a minor response (MR). Since eosinophil counts peaked 1 day after either the first or second course of the therapy, the posttreatment values were compared to each pretreatment level, with regard to the clinical antitumor response to this treatment. When patients who showed PR were defined as responders, absolute eosinophil counts and the percentage of eosinophils in responders after both the first and second courses of the therapy were significantly greater than each pretreatment value or the posttreatment level in nonresponders. Further, these findings were almost identical, when both PR and MR were considered to be a true remission and therefore patients who exhibited PR or MR were defined as responders, although the difference between posttreatment levels of eosinophils in responders and nonresponders was not significant at the second course. These results indicate that eosinophilia induced by this treatment correlates with the clinical response to this therapy.
authors.affiliation: Department of Surgery, Kyushu University, Beppu, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Arinaga
authors.forename: N
authors.initials: N
authors.lastname: Karimine
authors.forename: K
authors.initials: K
authors.lastname: Takamuku
authors.forename: S
authors.initials: S
authors.lastname: Nanbara
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: R
authors.initials: R
authors.lastname: Abe
authors.forename: D
authors.initials: D
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Matsuoka
authors.forename: H
authors.initials: H
authors.lastname: Ueo
authors.forename: T
authors.initials: T
authors.lastname: Akiyoshi
mesh_terms: D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004802:Eosinophilia / Q000139:chemically induced*; D004804:Eosinophils / Q000187:drug effects; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000494:pharmacology*; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy
chemical_list: D007376:Interleukin-2; D016685:Mitomycin